v3.26.1
Subsequent Events
6 Months Ended
Jun. 30, 2026
Subsequent Events [Abstract]  
Subsequent Events Subsequent Events
In July 2026, the Company entered into a collaboration agreement with Vertex Pharmaceuticals Inc. to develop multispecific T-cell engagers. The Company received $28.0 million upfront upon the execution of the agreement and is eligible for future milestones and tiered royalties.